LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates

Core Viewpoint - LivaNova reported quarterly earnings of $1.05 per share, exceeding the Zacks Consensus Estimate of $0.84 per share, and showing an increase from $0.93 per share a year ago, indicating a strong earnings surprise of +25.00% [1][2] Financial Performance - The company achieved revenues of $352.5 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 6.56% and up from $318.6 million year-over-year [2] - Over the last four quarters, LivaNova has consistently surpassed consensus EPS estimates four times and topped revenue estimates three times [2] Stock Performance - LivaNova shares have declined approximately 8% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.91 on revenues of $331.4 million, and for the current fiscal year, it is $3.65 on revenues of $1.32 billion [7] - The outlook for the Medical - Instruments industry, where LivaNova operates, is currently in the bottom 41% of Zacks industries, which may impact stock performance [8]